The Cardiac Exchange

Listen as Professor Pieter Kappetein discusses left atrial appendage management with Dr. Kelley Hutcheson of Baylor, Scott and White, Dr. Jeffrey Miller of Emory University School of Medicine , Dr. Basel Ramlawi of Lankenau Heart Institute and Dr. Gregory Rushing of University Hospitals.

Listen as Professor Pieter Kappetein discusses left atrial appendage management with Dr. Kelley Hutcheson of Baylor, Scott and White, Dr. Jeffrey Miller of Emory University School of Medicine , Dr. Basel Ramlawi of Lankenau Heart Institute and Dr. Gregory Rushing of University Hospitals.

Listen as Professor Pieter Kappetein discusses left atrial appendage management with Dr. Kelley Hutcheson of Baylor, Scott and White, Dr. Jeffrey Miller of Emory University School of Medicine , Dr. Basel Ramlawi of Lankenau Heart Institute and Dr. Gregory Rushing of University Hospitals.

Listen as Professor Pieter Kappetein, Chief Medical Officer and Vice President of Cardiac Surgery at Medtronic, speaks with Dr. Juan Crestanello of Mayo Clinic in Rochester, MN, Dr. Mark Cunningham of Brigham and Women's Hospital in Boston, MA, and Dr. Katherine Harrington of Baylor, Scott, and White in Plano, TX, about anticoagulation after bioprosthetic aortic valve replacement. Topics include: anticoagulation guideline compliance, medication options, strategies based on patient age, and thoughts on future practices.

Listen as Professor Pieter Kappetein, Chief Medical Officer and Vice President of Cardiac Surgery at Medtronic, speaks with Dr. Juan Crestanello of Mayo Clinic in Rochester, MN, Dr. Mark Cunningham of Brigham and Women's Hospital in Boston, MA, and Dr. Katherine Harrington of Baylor, Scott, and White in Plano, TX, about anticoagulation after bioprosthetic aortic valve replacement. Topics include: anticoagulation guideline compliance, medication options, strategies based on patient age, and thoughts on future practices.

Listen as Professor Pieter Kappetein, Chief Medical Officer and Vice President of Cardiac Surgery at Medtronic, speaks with Dr. Juan Crestanello of Mayo Clinic in Rochester, MN, Dr. Mark Cunningham of Brigham and Women's Hospital in Boston, MA, and Dr. Katherine Harrington of Baylor, Scott, and White in Plano, TX, about anticoagulation after bioprosthetic aortic valve replacement. Topics include: anticoagulation guideline compliance, medication options, strategies based on patient age, and thoughts on future practices.

Listen as Professor Pieter Kappetein, Chief Medical Officer and Vice President of Cardiac Surgery at Medtronic, speaks with Dr. Juan Crestanello of Mayo Clinic in Rochester, MN, Dr. Mark Cunningham of Brigham and Women's Hospital in Boston, MA, and Dr. Katherine Harrington of Baylor, Scott, and White in Plano, TX, about anticoagulation after bioprosthetic aortic valve replacement. Topics include: anticoagulation guideline compliance, medication options, strategies based on patient age, and thoughts on future practices.

Cardiac surgeons Dr. Michael Reardon from Houston Methodist and Dr. Bradley Leshnower from Emory University with interventional cardiologist Dr. Sachin Goel from Houston Methodist discuss SAVR versus TAVR. Topics include: which patients benefit from SAVR procedures, considerations for optimizing SAVR via root enlargement, and lifetime patient management as it relates to SAVR versus TAVR procedures.

Cardiac surgeons Dr. Michael Reardon from Houston Methodist and Dr. Bradley Leshnower from Emory University with interventional cardiologist Dr. Sachin Goel from Houston Methodist discuss SAVR versus TAVR. Topics include: which patients benefit from SAVR procedures, considerations for optimizing SAVR via root enlargement, and lifetime patient management as it relates to SAVR versus TAVR procedures.

Professor Pieter Kappetein, Chief Medical Officer and Vice President of Cardiac Surgery at Medtronic, sits down with four Cardiac Surgery residents and fellows for a candid chat. James Bailey, M.D., Tessa Watt, M.D., Daniel Ziazadeh, M.D., and Natalie Ostro, M.D. talk about their start in Cardiac Surgery, current challenges, workplace dynamics, and the future of the of the specialty.

Professor Pieter Kappetein, Chief Medical Officer and Vice President of Cardiac Surgery at Medtronic, sits down with four Cardiac Surgery residents and fellows for a candid chat. James Bailey, M.D., Tessa Watt, M.D., Daniel Ziazadeh, M.D., and Natalie Ostro, M.D. talk about their start in Cardiac Surgery, current challenges, workplace dynamics, and the future of the of the specialty.

Professor Pieter Kappetein, Chief Medical Officer and Vice President of Cardiac Surgery at Medtronic, sits down with four Cardiac Surgery residents and fellows for a candid chat. James Bailey, M.D., Tessa Watt, M.D., Daniel Ziazadeh, M.D., and Natalie Ostro, M.D. talk about their start in Cardiac Surgery, current challenges, workplace dynamics, and the future of the of the specialty.

Highlights from STS – Don't miss the discussions in which Dr. Gene Grossi from NYU talks with experts regarding the 2022 STS annual meeting. Our expert panel includes Dr. Jessica Forcillo from the University of Montreal, Dr. Shinichi Fukuhara from the University of Michigan, Dr. Jessica Luc of the University of British Columbia and Dr. Tom Nguyen from UCSF.

Highlights from STS – Don't miss the discussions in which Dr. Gene Grossi from NYU talks with experts regarding the 2022 STS annual meeting. Our expert panel includes Dr. Jessica Forcillo from the University of Montreal, Dr. Shinichi Fukuhara from the University of Michigan, Dr. Jessica Luc of the University of British Columbia and Dr. Tom Nguyen from UCSF.

Highlights from STS – Don't miss the discussions in which Dr. Gene Grossi from NYU talks with experts regarding the 2022 STS annual meeting. Our expert panel includes Dr. Jessica Forcillo from the University of Montreal, Dr. Shinichi Fukuhara from the University of Michigan, Dr. Jessica Luc of the University of British Columbia and Dr. Tom Nguyen from UCSF.

Highlights from STS – Don't miss the discussions in which Dr. Gene Grossi from NYU talks with experts regarding the 2022 STS annual meeting. Our expert panel includes Dr. Jessica Forcillo from the University of Montreal, Dr. Shinichi Fukuhara from the University of Michigan, Dr. Jessica Luc of the University of British Columbia and Dr. Tom Nguyen from UCSF.

Life-saving ECMO therapy continues to evolve. Tune in to this one-on-one interview, where Professor Pieter Kappetein, Chief Medical Officer and Vice President of Cardiac Surgery at Medtronic, talks with world-renowned surgeon and heralded "father of ECMO," Dr. Robert Bartlett. They discuss the evolution of ECMO since its inception and the key trends and guidelines driving life-saving ECMO changes today. Dr. Bartlett also shares his perspective on the key success factors for those interested in starting an ECMO program.

Life-saving ECMO therapy continues to evolve. Tune in to this one-on-one interview, where Professor Pieter Kappetein, Chief Medical Officer and Vice President of Cardiac Surgery at Medtronic, talks with world-renowned surgeon and heralded "father of ECMO," Dr. Robert Bartlett. They discuss the evolution of ECMO since its inception and the key trends and guidelines driving life-saving ECMO changes today. Dr. Bartlett also shares his perspective on the key success factors for those interested in starting an ECMO program.

Life-saving ECMO therapy continues to evolve. Tune in to this one-on-one interview, where Professor Pieter Kappetein, Chief Medical Officer and Vice President of Cardiac Surgery at Medtronic, talks with world-renowned surgeon and heralded "father of ECMO," Dr. Robert Bartlett. They discuss the evolution of ECMO since its inception and the key trends and guidelines driving life-saving ECMO changes today. Dr. Bartlett also shares his perspective on the key success factors for those interested in starting an ECMO program.

A discussion of the new controversial ACC/AHA guideline updates, which reduced the level of evidence for CABG as a treatment for CAD patients with 3-vessel disease and normal LV function. The panel provides a rebuttal on the benefits of CABG vs medical therapy and the reduction in class designation for CABG, as well as the use of the ISCHEMIA and other similar trials for drawing such comparative evidence conclusions.